References

Aleksova, A., Di Nucci, M., Gobbo, M., Bevilacqua, E., Pradella, et al (2015) Factor-V HR2 haplotype and thromboembolic disease. Acta Cardiologica. 70 (6): 707-11. doi: 10.2143/AC.70.6.3120184.

Beitelshees, A.L., Navare, H., Wang, D., Gong, Y., Wessel, J., Moss, J. I., Langaee, T. Y., Cooper-DeHoff, R. M., Sadee, W., Pepine, C. J., Schork, N. J., Johnson, J. A. (2009) CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response. Circulation, Cardiovascular Genetics. 2 (4): 362-70. doi: 10.1161/CIRCGENETICS.109.857839

Blake, C. M., Kharasch, E. D., Schwab, M., Nagele, P. (2013) A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. Clinical Pharmacology and Therapeutics. 94 (3): 394-9. doi: 10.1038/clpt.2013.96.

Brown, M. and Bussell, J. (2011). Medication Adherence: WHO Cares?. Mayo Clinic Proceedings, 86(4), pp.304-314.

Hamadeh, I. S., Langaee, T. Y., Dwivedi, R., Garcia, S., Burkley, B. M., Chapman, A. B., Johnson, J. A. (2014). Impact of CYP2D6 polymorphisms on clinical efficacy & tolerability of metoprolol tartrate. Clinical Pharmacology and Therapeutics, 96 (2): 175-181. http://doi.org/10.1038/clpt.2014.62

Bruzelius, M., Sweden, Bottai, M., Sweden, et al (2017) Predicting venous thrombosis in women using a combination of genetic markers and clinical risk factors. Journal of Thrombosis and Haemostasis, 13 (2): 219-227.

Di Stasi, S. L., MacLeod, T. D., Winters, J. D., & Binder-Macleod, S. A. (2010). Effects of Statins on Skeletal Muscle: A Perspective for Physical Therapists. Physical Therapy, 90(10), 1530-1542. http://doi.org/10.2522/ptj.20090251

Earle, N., Ingles, J., Bagnall, R. D., Gray, B., Crawford, J., Smith, W., Shelling, A. N., Love, D. R., Semsarian, C. & Skinner, J. R. (2015) NOS1AP Polymorphisms Modify QTc Interval Duration But Not Cardiac Arrest Risk in Hypertrophic Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 26 (12): 1346-1351.

Gan, G. G., Phipps, M. E., Lee, M. M., Lu, L. S., Subramaniam, R. Y., Bee, P. C. & Chang, S. H. (2011) Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations. Ann Hematol, 90 (6): 635-641.

Hernández-Hernández, R., Sosa-Canache, B., Velasco, M., Armas-Hernandez, M. J., Armas-Padilla, M. C. & Cammarata, R. (2002) Angiotensin II receptor antagonists role in arterial hypertension. Journal of human hypertension, 16 (1): S93.

Johnson, J., Gong, L., Whirl-Carrillo, M., Gage, B., Scott, S., Stein, C., Anderson, J., Kimmel, S., Lee, M., Pirmohamed, M., Wadelius, M., Klein, T. & Altman, R. (2011) Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing. Clinical Pharmacology and Therapeutics, 90 (4): 625-629. http://doi.org/10.1038/clpt.2011.185

Liggett, S. B., Cresci, S., Kelly, R. J., Syed, F. M., Matkovich, S. J., Hahn, H. S., Diwan, A., Martini, J. S., Sparks, L., Parekh, R. R., Spertus, J. A., Koch, W. J., Kardia, S. L. & Dorn, G. W., 2nd (2008) A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med, 14 (5): 510-517.

Liggett, S. B., Mialet-Perez, J., Thaneemit-Chen, S., Weber, S. A., Greene, S. M., Hodne, D., Nelson, B., Morrison, J., Domanski, M. J., Wagoner, L. E., Abraham, W. T., Anderson, J. L., Carlquist, J. F., Krause-Steinrauf, H. J., Lazzeroni, L. C., Port, J. D., Lavori, P. W. & Bristow, M. R. (2006) A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A, 103 (30): 11288-11293.

Liu, J., Jiang, H. H., Wu, D. K., Zhou, Y. X., Ye, H. M., Li, X., Luo, Z. Y., Guo, Z., Zhang, Y. L., Wang, Y. C., Zhang, W., Zhou, H. H. & Wang, L. S. (2015) Effect of gene polymorphims on the warfarin treatment at initial stage. Pharmacogenomics J, McLean, P. G., Ahluwalia, A. & Perretti, M. (2000) Association between Kinin B1 Receptor Expression and Leukocyte Trafficking across Mouse Mesenteric Postcapillary Venules. J Exp Med, 192 (3): 367-380.

Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W., Braunwald, E. & Sabatine, M. S. (2009) Cytochrome P-450 Polymorphisms and Response to Clopidogrel. New England Journal of Medicine, 360 (4): 354-362.

Montó, F., Oliver, E., Vicente, D., Rueda, J., Agüero, J., Almenar, L., Ivorra, M. D., Barettino, D. & D''Ocon, P. (2012) Different expression of adrenoceptors and GRKs in the human myocardium depends on heart failure ethiology and correlates to clinical variables. American Journal of Physiology - Heart and Circulatory Physiology, 303 (3): H368.

National Clinical Guidelines Centre (UK) (2011). Stable Angina: Methods, Evidence & Guidance [Internet]. London: Royal College of Physicians (UK); (NICE Clinical Guidelines, No. 126.) 7, Beta blockers vs. calcium channel blockers. Available from: https://www.ncbi.nlm.nih.gov/books/NBK83601/

Ornelas, W. L. H. B. (2008) SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med, 2008 (359): 789-799.

Oscarson, M., Hidestrand, M., Johansson, I. & Ingelman-Sundberg, M. (1997) A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol Pharmacol, 52 (6): 1034-1040.

Pacanowski, M. A., Zineh, I., Li, H., Johnson, B. D., Cooper-DeHoff, R. M., Bittner, V., McNamara, D. M., Sharaf, B. L., Merz, C. N. B., Pepine, C. J. & Johnson, J. A. (2008) Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women''s Ischemia Syndrome Evaluation. Journal of Translational Medicine, 6 11-11.

Pasanen, M. K., Neuvonen, M., Neuvonen, P. J. & Niemi, M. (2006) SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenetics and genomics, 16 (12): 873-879.

Romkes, M., Faletto, M. B., Blaisdell, J. A., Raucy, J. L. & Goldstein, J. A. (1991) Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry, 30 (13): 3247-3255.

Van Noord, C., Aarnoudse, A.-J. L. H. J., Eijgelsheim, M., Sturkenboom, M. C. J. M., Straus, S. M. J. M., Hofman, A., Kors, J. A., Newton-Cheh, C., Witteman, J. C. M. & Stricker, B. H. C. (2009) Calcium channel blockers, NOS1AP, and heart-rate-corrected QT prolongation. Pharmacogenetics and Genomics, 19 (4):

Wieloch, M., Hillarp, A., Strandberg, K., Nilsson, C. & Svensson, P. J. (2009) Comparison and evaluation of a Point-of-care device (CoaguChek XS) to Owren-type prothrombin time assay for monitoring of oral anticoagulant therapy with warfarin. Thrombosis Research, 124 (3): 344-348.

World Health Organization. (2017). ADHERENCE TO LONG-TERM THERAPIES: EVIDENCE FOR ACTION. [online] Available at: http://www.who.int/chp/knowledge/publications/adherence_report/en/ [Accessed 8 Aug. 2017].

Support
Follow Us On
Facebook Twitter Instagram LinkedIn YouTube

© 2017 Rightangled LTD. All Rights Reserved.